M‐Pharma B.V., a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and Pfizer Inc. (NYSE:PFE) announced today that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.

Bayer's once-daily oral anticoagulant Xarelto® (rivaroxaban) has been approved by the China Food and Drug Administration (CFDA) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.

H. Lundbeck A/S (Lundbeck) today announced that the Board of Directors of the company has appointed Kåre Schultz as new president and CEO of Lundbeck. Kåre Schultz will take up his new position on 20 May 2015.

The Bayer Group had a strong start to 2015 and once again expanded sales in the first quarter. Sales of the Bayer Group moved ahead in the first quarter of 2015 by 14.8 percent to EUR 12,117 million (Q1 2014: EUR 10,555 million).

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack.

With numerous marketing authorisations for medicines and product launches in 2014, the research-driven pharmaceutical company Boehringer Ingelheim is now positioned for future growth.

AstraZeneca and MedImmune, the Company's global biologics research and development arm, have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune.